Clinical trial · Observational
Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management
Real-world Incremental Costs of Opportunistic Upper Gastrointestinal Endoscopy Added to Colorectal Cancer Screening and the Economic Burden of Gastric Cancer Management: a Retrospective Cohort Study - Study Protocol
NCT07522320CI-TRIAL-00118582EconROGCASactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Data will be extracted from routinely collected hospital databases.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Adenocarcinoma | Gastric Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastric Cancer (GC) | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort A - Opportunistic screening cohort
- description
- Cohort B - Gastric cancer cohort
Primary outcomes (3)
- measure
- Stage distribution at diagnosis
- timeFrame
- At diagnosis (2015-2020)
- description
- Distribution of gastric cancer stages at diagnosis (Stage I-IV) according to TNM classification (expressed as percentage of patients per stage).
- measure
- Treatment patterns
- timeFrame
- During initial treatment period (2015-2020)
- description
- Types of treatment received by patients with gastric cancer, including surgery, chemotherapy, radiotherapy, and palliative care
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Cohort A: * Eligible participants were adults aged 50 to 75 years or older who had been referred for colonoscopy as part of the national colorectal cancer screening programme, following a positive FIT. To be included, individuals also needed to provide informed consent and agree to undergo an EGD endoscopy for the screening of potential upper gastrointestinal precancerous conditions or lesions. Cohort B: * Patients with gastric adenocarcinoma, diagnosed and treated at Unidade Local de Saúde do Alto Alentejo between 2015 and 2025. Exclusion Criteria: Cohort A: * Exclusion criteria included a prior diagnosis of gastric cancer, as well as any condition that would prevent the safe performance of the EGD or the collection of gastric mucosal biopsies. Previous EGD was not listed as an exclusion criterion. Cohort B: * Other types of gastric tumors. * Gastric involvement from metastatic disease of another primary tumor.
References
Publications (5)
- BACKGROUNDAreia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J. 2018 Mar;6(2):192-202. doi: 10.1177/2050640617722902. Epub 2017 Jul 18. PMID 29511549
- BACKGROUNDLansdorp-Vogelaar I, Meester RGS, Laszkowska M, Escudero FA, Ward ZJ, Yeh JM. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol. 2021 Mar-Apr;50-51:101735. doi: 10.1016/j.bpg.2021.101735. Epub 2021 Feb 22. PMID 33975689
- BACKGROUNDMourato MB, Pratas N, Branco Pereira A, Tare F, Chanca R, Fronteira I, Dinis R, Areia M. Effectiveness of Gastric Cancer Endoscopic Screening in Intermediate-Risk Countries: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc. 2025 Feb 3;14:e56791. doi: 10.2196/56791. PMID 39545590
- BACKGROUNDMourato MB, Pratas N, Branco Pereira A, Costa Pinto F, Dinis R, Fronteira I, Areia M. Gastric Cancer Endoscopic Screening in an Intermediate-Risk Country-A Dual-Center Pilot Program. Helicobacter. 2025 Jul-Aug;30(4):e70061. doi: 10.1111/hel.70061. PMID 40762368
- BACKGROUNDIshii N, Shiratori Y, Ishikane M, Omata F. Population effectiveness of endoscopy screening for mortality reduction in gastric cancer. DEN Open. 2023 Sep 19;4(1):e296. doi: 10.1002/deo2.296. eCollection 2024 Apr. PMID 37731836